Regan J. Lauer - Sep 1, 2023 Form 4 Insider Report for ImmunityBio, Inc. (IBRX)

Role: Chief Accounting Officer
Signature: /s/ Jason Liljestrom, as Attorney-in-Fact
Stock symbol: IBRX
Transactions as of: Sep 1, 2023
Transactions value $: $0
Form type: 4
Date filed: 9/6/2023, 07:40 PM
Previous filing: Aug 28, 2023
Next filing: Dec 19, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	IBRX	Common Stock	Options Exercise	$0	+32.9K	+156.31%	$0.00	53.9K	Sep 1, 2023	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	IBRX	Restricted Stock Units	Options Exercise	$0	-32.9K	-50%	$0.00	32.9K	Sep 1, 2023	Common Stock	32.9K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
F2	Subject to the reporting person's continuing to be a Service Provider (as defined in the Amended and Restated 2015 Equity Incentive Plan) through each applicable vesting date, fifty percent (50%) of the RSUs subject to the award vested on September 1, 2023 and the remaining fifty percent (50%) of the RSUs subject to the award shall vest on January 31, 2024.